文献速递角膜与眼表疾病

抗菌蓝光治疗感染性角膜炎:离体与在体研究

Antimicrobial Blue Light Therapy for Infectious Keratitis: Ex Vivo and In Vivo Studies.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2017-01-01

研究建立兔离体与小鼠在体感染性角膜炎模型,以生物发光铜绿假单胞菌实时监测感染程度,评估415 nm抗菌蓝光在不同辐射暴露下于接种后6或24小时治疗的效果,并将到达视网膜的暴露量与ANSI标准比较以估计视网膜安全性。单次暴露后离体与在体感染角膜细菌负荷均快速显著降低(>2-log10),但在体小鼠蓝光暴露后24小时观察到感染复发;结论认为抗菌蓝光是感染性角膜炎的潜在替代或辅助治疗,需用眼部解剖接近人类的大动物模型进一步研究角膜与视网膜安全性。

要点

  • 感染角膜细菌发光与菌落形成单位线性相关(R2=0.921)。
  • 单次抗菌蓝光暴露后离体与在体感染角膜细菌负荷均降低>2-log10。
  • 在体小鼠蓝光暴露后24小时观察到感染复发。

核心结论

  • 抗菌蓝光是感染性角膜炎的潜在替代或辅助治疗。
  • 需用眼部解剖与人类相似的大动物模型进一步研究角膜与视网膜安全性。

研究设计与样本

  • 研究建立离体兔模型和在体小鼠模型,使用生物发光铜绿假单胞菌作为致病菌,通过生物发光成像实时无创监测感染范围。
  • 细菌发光定量与菌落形成单位(CFU)相关。
  • 在离体与在体模型中评估415 nm抗菌蓝光在细菌接种后6或24小时递送时按辐射暴露量变化的治疗效果。
  • 将计算到达视网膜的抗菌蓝光暴露量与美国国家标准学会(ANSI)标准比较以估计视网膜安全性。

主要发现

  • 铜绿假单胞菌角膜炎在离体与在体模型中于接种后24小时完全形成。
  • 感染角膜细菌发光与CFU呈线性相关(R2=0.921)。
  • 离体与在体感染角膜在单次抗菌蓝光暴露后细菌负荷均快速显著降低(>2-log10)。
  • 蓝光暴露后24小时在蓝光治疗的小鼠中观察到感染复发。
  • 抗菌蓝光对视网膜的毒性很大程度上取决于角膜对抗菌蓝光的透过。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 蓝光暴露后24小时在蓝光治疗的小鼠中观察到感染复发。
  • 需用眼部解剖与人类相似的大动物模型进一步研究角膜与视网膜安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the effectiveness of antimicrobial blue light (aBL) as an alternative or adjunctive therapeutic for infectious keratitis. METHODS: We developed an ex vivo rabbit model and an in vivo mouse model of infectious keratitis. A bioluminescent strain of Pseudomonas aeruginosa was used as the causative pathogen, allowing noninvasive monitoring of the extent of infection in real time via bioluminescence imaging. Quantitation of bacterial luminescence was correlated to colony-forming units (CFU). Using the ex vivo and in vivo models, the effectiveness of aBL (415 nm) for the treatment of keratitis was evaluated as a function of radiant exposure when aBL was delivered at 6 or 24 hours after bacterial inoculation. The aBL exposures calculated to reach the retina were compared to the American National Standards Institute standards to estimate aBL retinal safety. RESULTS: Pseudomonas aeruginosa keratitis fully developed in both the ex vivo and in vivo models at 24 hours post inoculation. Bacterial luminescence in the infected corneas correlated linearly to CFU (R2 = 0.921). Bacterial burden in the infected corneas was rapidly and significantly reduced (>2-log10) both ex vivo and in vivo after a single exposure of aBL. Recurrence of infection was observed in the aBL-treated mice at 24 hours after aBL exposure. The aBL toxicity to the retina is largely dependent on the aBL transmission of the cornea. CONCLUSIONS: Antimicrobial blue light is a potential alternative or adjunctive therapeutic for infectious keratitis. Further studies of corneal and retinal safety using large animal models, in which the ocular anatomies are similar to that of humans, are warranted.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Zhu H, Kochevar IE, Behlau I, et al. Antimicrobial Blue Light Therapy for Infectious Keratitis: Ex Vivo and In Vivo Studies. Invest Ophthalmol Vis Sci. 2017. PMID: 28129422. doi:10.1167/iovs.16-20272

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。